

Aurobindo's profit down 22% at ₹611 cr

OUR BUREAU

Hyderabad, November 13

Aurobindo Pharma's consolidated net profit decreased 22 per cent at ₹611 crore in the second quarter ended September 30, 2018 as compared to ₹781 crore in the corresponding quarter of the previous year.

The total revenue of the Hy-

derabad-based company increased by 7 per cent at ₹4,751 crore as against ₹4,436 crore.

Terming the company's performance as 'healthy', its Managing Director N. Govindarajan, Managing Director, said, "Our focused efforts to commercialise differentiated product baskets are aimed at creating sustainable profit-

ability for the future." The company filed two Abbreviated New Drug Applications (ANDAs) in dermatology and one nasal ANDA in the first half of the fiscal.

The board had approved an interim dividend at 125 pc, i.e., ₹1.25 per equity share of ₹1 for the financial year 2018-19.